Enterome signs major strategic R&D collaboration with Nestlé Health Science to develop and commercialize new AllerMimics and EndoMimics immunotherapies for food allergies and inflammatory bowel disease

Enterome and Nestlé Health Science will co-develop Enterome's lead EndoMimics compound, EB1010, a potent local inducer of IL-10 targeting food allergies and inflammatory bowel disease (IBD).

Related Keywords

Paris ,France General ,France ,Hans Juergen Woerle ,Prnewswire Enterome ,Pierre Belichard ,Sylvie Berrebi Mark ,Christophe Bonny ,Head Of External Communications ,Health Science ,Chief Scientific Officer ,Juergen Woerle ,Chief Scientific ,Medical Officer ,External Communications ,Mark Swallow ,Enterome ,Signs ,Major ,Strategic ,Collaboration ,Nestl 233 ,Health ,Science ,Evelop ,Ommercialize ,Llermimics ,Ndomimics ,Mmunotherapies ,Wood ,Allergies ,Inflammatory ,Towel ,Disease ,